Agomab doses first patient in NOV — ERA Phase 2b trial of ontunisertib in fibrostenosing Crohn’s disease
Agomab began dosing in NOV-ERA, a global Phase 2b trial of ontunisertib for symptomatic fibrostenosing Crohn’s disease. Earlier Phase 2a STENOVA results were already presented, supporting continued late-stage development of the anti-fibrotic program. The study will test whether ontunisertib improves bowel narrowing out